FOSTER CITY, Calif. / Feb 09, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced the company has been named one of America’s Most JUST Companies. The ranking, presented by JUST Capital and CNBC, reflects Gilead’s longstanding commitment to operate responsibly by prioritizing stakeholder engagement – including with the patients and communities the company serves, employees and shareholders – while working to create a healthier world for all people. Gilead was recognized on the top 100 list and ranked fifth in the Pharmaceuticals and Biotech industry.
“We have set ambitious goals that are helping to further embed corporate responsibility into our business and honor our commitment to create a better world for future generations,” said Carmen Villar, Vice President, Public Affairs, Gilead Sciences. “We are proud to cultivate sustainable practices and an inclusive culture, while providing equitable opportunities for the communities we serve.”
Gilead’s Environmental, Social and Governance (ESG) strategy aims to position the company as the biotech employer and partner of choice while delivering shareholder value in a sustainable, responsible manner. Examples of Gilead’s commitment to ESG include:
Each year, JUST Capital collects and analyzes corporate data to evaluate the 1,000 largest public U.S. companies across 20 issues identified through comprehensive, ongoing public opinion research on Americans’ attitudes toward responsible corporate behavior. For more about the JUST Capital rankings, visit: https://justcapital.com/reports/just-capital-and-cnbc-release-the-2024-rankings-of-americas-most-just-companies/
This recognition follows Gilead’s recent announcement it was named to the Dow Jones Sustainability World Index for the third consecutive year, as well as the Dow Jones Sustainability North America Index, which highlight the most sustainable companies around the world based on a corporate sustainability assessment.
Details on Gilead’s ESG commitments, goals and progress can be found in the company’s Environmental Social Governance Impact Report, which is based on internationally recognized guidelines from the Global Reporting Initiative, the Sustainability Accounting Standards Board, the Taskforce on Climate Related Financial Disclosures and the United Nations Sustainable Development Goals. Learn more about Gilead’s commitment to ESG at https://www.gilead.com/purpose/esg.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Gilead and the Gilead logo are registered trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).
Last Trade: | US$88.40 |
Daily Change: | -3.71 -4.03 |
Daily Volume: | 11,352,698 |
Market Cap: | US$109.620B |
November 15, 2024 November 13, 2024 November 12, 2024 November 07, 2024 November 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB